Despite the wave of criticism that has followed the U.S. Food and Drug Administration’s emergency approval of convalescent plasma to treat COVID-19 patients, infectious disease experts say the therapy remains promising.
Medical Express interviewed physicians running trials studying convalescent plasma treatments in the United States.
I cannot think of one shred of data that I have seen that would suggest harm. What I think everybody agrees on is the gaps of knowledge that exist can best be addressed by high-quality trials.Dr. Liise-anne Pirofski, chair of biomedical research at the Albert Einstein College of Medicine and Montefiore Medical Center